Tirzepatide, the Eli Lilly dual-hormone drug sold for weight loss as Mounjaro and for obesity as Zepbound, quieted nearly every sign of nicotine's pull in a cage of male mice. It did not touch a single smoker.
Published in the British Journal of Pharmacology ↗, a team at the University of Gothenburg's Addiction Biology Unit gave nicotine-exposed male mice tirzepatide ↗, a long-acting agonist of both the GLP-1 receptor ↗ and the GIP receptor, and watched the animals' reward machinery go flat. The drug cut nicotine-driven hyperactivity in a dose-dependent way, blunted the place-preference test (a standard readout where a mouse learns to loiter in the spot where it last got a drug), and lowered the dopamine surge in the nucleus accumbens, the brain's central reward relay. It also suppressed relapse-like behavior after a period of abstinence and blocked the dopamine spikes in the ventral tegmental area and the lateral septum, two other nodes of the same circuit.
It did more than damp dopamine. The animals' GABA levels, the brain's main brake signal, were restored region by region, which hints that these incretin drugs reach into reward circuitry more broadly than the tidy dopamine story suggests. For a class most people know only as an appetite switch, that is a real mechanistic finding.
Here is what the study does not give you: magnitudes. The report describes directions, not sizes. Tirzepatide attenuated, reduced, suppressed. How much, at what dose, in how many animals stays behind the verbs. Direction without magnitude is a fine place to start a program and a poor place to end an argument.
And these were mice. Male mice, which means the work cannot speak to half the population any eventual drug would treat. Conditioned place preference and locomotor sensitization are models of reward and relapse, not of a person deciding at 7 a.m. whether to buy a pack. The human evidence for incretin drugs against nicotine is small and early. A pilot trial of the older GLP-1 drug exenatide ↗, AstraZeneca's Byetta, tested it against a placebo in 84 overweight smokers who were already wearing a nicotine patch, at UTHealth in Houston. Published in Nicotine and Tobacco Research ↗, it lifted six-week quit rates to 46 percent from 27 percent and trimmed post-quit weight by about five and a half pounds. The catch: the interval around that quit effect ran from 0.96 to 3.27, meaning it brushed against no effect at all, in a sample of 84 people. A dedicated tirzepatide smoking-cessation trial in people is only now getting underway.
That is the honest shape of this. Peptidemodel hosts tirzepatide as a card built against the GLP-1 and GIP receptors, and its file is thick with metabolic trial data and thin on anything neurological, which is about where the whole field sits. The mouse work is the strongest kind of preclinical signal: several converging behavioral tests, a coherent circuit story, a plausible mechanism. It is also the reason to run the human trial, not the result of one. The distance between a flattened dopamine curve in Gothenburg and a person who stays quit is the entire trip this drug still has to make.